Breaking Down Inner Mongolia Furui Medical Science Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) is a growth story or a valuation squeeze? In the first half of 2025 the company posted operating revenue of 713 million yuan (up 11.02% year‑on‑year) while net profit attributable to shareholders fell to 51.934 million yuan (down 31.09% YoY), even as trailing‑twelve‑month revenue through 30 Sept 2025 reached 1.47 billion yuan (+10.83% YoY) and market capitalization stood at 17.96 billion yuan as of 20 Nov 2025; juxtapose that growth with a TTM gross profit margin of 74.13% and an ROE of 6.48%, a lofty trailing P/E of 142.83 and forward P/E of 94.52, conservative leverage (debt‑to‑equity 0.44, asset‑to‑equity 30.44%) and strong liquidity (current ratio 2.5, cash ratio 1.2) alongside risks like a 27.38% drop in operating cash flow to 2.21 billion yuan for the nine months ending 30 Sept 2025, projected FX losses of ~15.2 million yuan and rising share‑based payments, while R&D investment of 148 million yuan (10.98% of revenue) and analyst forecasts of double‑digit revenue and earnings growth suggest clear avenues to explore in the sections ahead

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Revenue Analysis

• H1 2025 operating revenue: 713 million yuan (+11.02% YoY)
• H1 2025 net profit attributable to shareholders: 51.934 million yuan (-31.09% YoY)
• TTM revenue (as of 2025-09-30): 1.47 billion yuan (+10.83% YoY)

• Top-line growth: H1 and TTM revenue increases (~11% and ~10.8%) show sustained demand or expanded sales footprint.
• Profitability squeeze: 31.09% decline in H1 net profit suggests rising costs, margin compression, increased SG&A or R&D spend, or non-recurring charges.
• Labor productivity: Revenue per employee ≈ 1.70 million yuan positions the company relative to peers for operational efficiency assessment.
• Valuation context: P/S of 11.96 and market cap of 17.96 billion yuan imply premium expectations for future growth or high margin recovery.

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Profitability Metrics

• Reporting period: TTM ending September 30, 2025 (unless otherwise stated).
• Gross profit margin: 74.13% - indicates high product/service-level profitability and favorable cost structure.
• Operating margin: 20.49% - reflects efficient control of operating expenses relative to revenues.
• Net profit margin: 7.31% - shows solid bottom-line conversion after taxes, interest, and non-operating items.
• Return on equity (ROE): 6.48% - modest return to shareholders, down slightly from 6.56% the prior year.
• Basic earnings per share (EPS): 0.47 yuan (TTM); Price-to-earnings (P/E) ratio: 142.83 - implies market is pricing in significant growth or valuation premium.
• Net profit (2024): 113 million yuan, up 11.54% year-over-year - an indicator of continued profitability growth.

• High gross margin suggests strong product mix or pricing power; operating margin indicates management efficiency but the gap to net margin points to non-operating costs or tax impacts worth monitoring.
• ROE decline is marginal; investors should watch leverage, share issuance, and retained earnings trends that influence ROE trajectory.
• Elevated P/E (142.83) relative to EPS (0.47 yuan) signals market expectations of future growth - validate against revenue growth, R&D pipeline, and margin sustainability.

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Debt vs. Equity Structure

• Total assets: ¥1.47 billion
• Total liabilities: ¥448 million
• Implied shareholders' equity: ¥1.022 billion (assets - liabilities)
• Asset-to-equity ratio (reported): 30.44%
• Debt-to-equity ratio: 0.44
• Market capitalization: ¥17.96 billion (264.98 million shares outstanding)
• Enterprise value: ¥17.76 billion

• The low debt-to-equity ratio (0.44) indicates limited reliance on external debt financing relative to equity.
• The alignment of enterprise value and market capitalization suggests net debt is minimal relative to market value.
• A substantial market cap (¥17.96B) against book equity (¥1.022B) reflects investor valuation premium and growth expectations.

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for Inner Mongolia Furui Medical Science Co., Ltd. indicate a solid short-term position and manageable leverage, supported by strong cash holdings and operating cash flow generation despite a year-over-year decline.

• Current ratio: 2.5 - sufficient short-term assets to cover liabilities.
• Quick ratio: 1.8 - good liquidity without relying on inventory.
• Cash ratio: 1.2 - healthy cash position relative to current liabilities.
• Interest coverage ratio: 5 - ample ability to meet interest obligations.
• Operating cash flow (9 months ending Sep 30, 2025): ¥2.21 billion - down 27.38% YoY.
• Short-term debt: low level - reduced immediate liquidity risk.

Areas for monitoring include the YoY decline in operating cash flow and its drivers (working capital changes, capex timing, or revenue mix). For additional corporate context and strategic positioning, see Mission Statement, Vision, & Core Values (2026) of Inner Mongolia Furui Medical Science Co., Ltd.

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Valuation Analysis

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) shows valuation multiples that point to elevated market expectations and a premium assigned to its earnings, assets and revenue base. Key quoted metrics are summarized below and followed by interpretive notes to guide investors.

• Trailing P/E: 142.83 - indicates investors are paying a high multiple of last-12-months earnings.
• Forward P/E: 94.52 - still high, but lower than trailing P/E, suggesting expected earnings growth or analyst upgrades.
• P/B: 7.58 - the market values the company's book equity significantly above carrying value.
• P/S: 12.10 - investors are pricing in substantial future revenue expansion or margin improvement.
• EV/Revenue: 6.18 - the enterprise value implies a sizeable premium per unit of revenue.
• EV/EBITDA: 24.07 - a premium multiple versus many peers, signaling high expectations for profitability or scarce comparable assets.
• 1Y Market Cap change: +32.45% - strong investor sentiment over the past year.

Contextual considerations for these multiples:

• High P/E and P/S commonly arise from low current earnings, high expected growth, or both; reconcile with recent EPS trends and guidance.
• P/B at 7.58 suggests either substantial intangible assets not captured on the balance sheet or investor expectations of above-normal ROE going forward.
• EV/EBITDA of 24.07 implies little margin for error; operational setbacks could compress returns for shareholders.
• Positive 1-year market cap momentum (+32.45%) can reflect successful product launches, contract wins, or broader sector re-rating-verify drivers in recent disclosures.

For background on the company's history, ownership and business model, see: Inner Mongolia Furui Medical Science Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) - Risk Factors

Key risk exposures and financial deterioration indicators investors should monitor for Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ).

• Currency risk: management projects a foreign exchange loss of approximately ¥15.2 million due to USD depreciation against the EUR.
• Profitability pressure: net profit attributable to shareholders in H1 2025 decreased by 31.09% year‑on‑year.
• Equity incentive burden: forecasted share‑based payment expense of ¥12.4 million (up from ¥5.2 million previously), more than doubling the prior charge.
• Margin compression: gross profit margin has slightly declined versus the prior year, signaling potential cost or pricing pressure.
• Valuation risk: the company currently trades at a relatively high P/E ratio compared with peers, suggesting possible overvaluation.
• Cash flow deterioration: operating cash flow fell by 27.38% year‑on‑year, raising sustainability concerns for operations and growth investments.

For context on the company's broader strategy, ownership and historical performance, see: Inner Mongolia Furui Medical Science Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) Growth Opportunities

• R&D commitment: the company reported total R&D expenditure of 148 million yuan, representing 10.98% of revenue (implied revenue ≈ 1,348.8 million yuan).
• Analyst growth outlook: consensus forecasts earnings growth of ~45.0% per annum and revenue growth of ~22.1% per annum.
• Product expansion: continued development and commercialization of the FibroScan series of liver fibrosis diagnostic instruments, plus pipeline diversification across non-invasive diagnostics.
• Market expansion: scalable opportunity across domestic hospitals and county-level healthcare facilities, with international export potential to Asia and emerging markets.
• Strategic M&A: management is exploring acquisitions to acquire complementary technologies, expand distribution channels, and accelerate scale.
• Macro demand: rising prevalence of liver disease and growing demand for innovative, non-invasive medical devices support long-term volume growth and pricing power.

• Key operational levers to watch: R&D-to-revenue conversion (commercialization rate of FibroScan and new devices), reimbursement approvals, domestic tender wins, export contracts, and any announced acquisitions or partnerships.
• Investor considerations: how incremental R&D (148 million spent) translates into product sales and margin expansion under the analysts' projected revenue and earnings growth paths.